Besides PD-L1 TPS, microsatellite instability (MSI)/mismatch repair deficiency and tumor mutational burden (TMB) have been approved as ICI biomarkers by the Food and Drug Administration (FDA) [11,12]. Here, CD274 is linked to neoplasm.